ArticleThe Biochemical journal2005
Mucin glycosylation changes in cystic fibrosis lung disease are not manifest in submucosal gland secretions.
Article in The Biochemical journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 48 citations in OpenAlex.
- Salivary mucin MUC7 oligosaccharides in patients with recurrent aphthous stomatitis.Clinical oral investigations · 2015Trial
- B3GNT7 regulates mucin glycosylation and protects against colitis and infection.bioRxiv : the preprint server for biology · 2026Article
- Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence.American journal of respiratory cell and molecular biology · 2022Article
- Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using in situ proximity ligation assay.Glycobiology · 2021Article
- Discovery of N-glycan Biomarkers for the Canine Osteoarthritis.Life (Basel, Switzerland) · 2020Article
- Mucins: the frontline defence of the lung.Biochemical Society transactions · 2018Review
- The Densely O-Glycosylated MUC2 Mucin Protects the Intestine and Provides Food for the Commensal Bacteria.Journal of molecular biology · 2016Review
- COPD immunopathology.Seminars in immunopathology · 2016Review
- Reduced Mucin-7 (Muc7) Sialylation and Altered Saliva Rheology in Sjögren's Syndrome Associated Oral Dryness.Molecular & cellular proteomics : MCP · 2016Article
- Acidic pH increases airway surface liquid viscosity in cystic fibrosis.The Journal of clinical investigation · 2016Article
- Mimicking the host and its microenvironment in vitro for studying mucosal infections by Pseudomonas aeruginosa.Pathogens and disease · 2014Review
- Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer.Journal of chromatography. A · 2013Article
- Cellular and molecular biology of airway mucins.International review of cell and molecular biology · 2013Review
- Smoking and lung cancer-induced changes in N-glycosylation of blood serum proteins.Glycobiology · 2012Article
- Structural analysis of N- and O-glycans released from glycoproteins.Nature protocols · 2012Article
- Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers.The Analyst · 2011Article
- Effects of Muclin (Dmbt1) deficiency on the gastrointestinal system.American journal of physiology. Gastrointestinal and liver physiology · 2008Article
- Mucin granule intraluminal organization.American journal of respiratory cell and molecular biology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SMG (submucosal gland) secretions are a major component of the airway surface liquid, are associated with innate immunity in the lung, and have been reported to be altered in lung disease. Changes in lung mucosal glycosylation have been reported in CF (cystic fibrosis), which may be responsible for differential bacterial binding to glycosylated components in the lung mucosa and hence increased pre-disposition to pulmonary infection. Glycoproteomic analysis was performed on SMG secretions collected from explanted bronchial tissue of subjects with severe lung disease, with and without CF, and controls without lung disease. Mucins MUC5B and MUC5AC were shown to be the dominant high-molecular-mass glycoprotein components, with a minor non-mucin glycoprotein component, gp-340, also present. Oligosaccharides containing blood-group determinants corresponding to subjects' blood type were abundant on MUC5B/MUC5AC, as were Lewis-type epitopes and their sialylated analogues, which are ligands for pathogens and leucocytes. No significant differences were found in the glycosylation of MUC5B/MUC5AC or gp-340 between CF and non-CF subjects with severe lung disease, implying that CF does not influence SMG secretion mucin glycosylation in end-stage lung disease. There were also no significant differences found in the glycosylation of these components in severe lung disease compared with non-diseased lungs. This suggests that previously reported changes in the glycosylation of respiratory glycoconjugates in CF, and other pulmonary conditions, are not due to the glycosylation of components in SMG secretions, but may involve other secretions, responses or extracellular factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.